Becton, Dickinson and Company's (BDX) "Hold (C-)" Rating Reiterated at Weiss Ratings

Key Points

• Becton, Dickinson and Company (BDX) has had its "hold (C-)" rating reaffirmed by Weiss Ratings, indicating a cautious outlook on the stock.
• Analysts have varying target prices for BDX, with the average set at $205.40, reflecting a mix of buy and hold ratings from different institutions.
• In its last earnings report, BDX reported a 10.4% increase in revenue year-over-year, with earnings per share exceeding consensus estimates.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report)'s stock had its "hold (c-)" rating reissued by Weiss Ratings in a report released on Wednesday,Weiss Ratings reports.

BDX has been the topic of several other research reports. Argus lifted their target price on shares of Becton, Dickinson and Company from $220.00 to $230.00 in a report on Monday, September 15th. Royal Bank Of Canada started coverage on Becton, Dickinson and Company in a research report on Thursday, September 25th. They set a "sector perform" rating and a $211.00 target price on the stock. Morgan Stanley lifted their price objective on Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an "overweight" rating in a report on Monday, August 11th. Wall Street Zen upgraded shares of Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a research report on Saturday, August 9th. Finally, Wells Fargo & Company boosted their price objective on Becton, Dickinson and Company from $172.00 to $184.00 and gave the company an "equal weight" rating in a research report on Friday, August 8th. Three analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and an average target price of $205.40.

Becton, Dickinson and Company Trading Up 0.7%

Shares of BDX stock traded up $1.32 during trading hours on Wednesday, hitting $193.85. 1,111,876 shares of the company were exchanged, compared to its average volume of 2,464,488. The firm has a fifty day moving average of $189.41 and a 200 day moving average of $186.83. The company has a quick ratio of 0.62, a current ratio of 1.10 and a debt-to-equity ratio of 0.69. Becton, Dickinson and Company has a 1 year low of $163.33 and a 1 year high of $251.99. The firm has a market cap of $55.56 billion, a PE ratio of 34.87, a PEG ratio of 1.50 and a beta of 0.25.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share for the quarter, topping analysts' consensus estimates of $3.40 by $0.28. The company had revenue of $5.51 billion for the quarter, compared to the consensus estimate of $5.50 billion. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. Becton, Dickinson and Company's revenue was up 10.4% on a year-over-year basis. During the same quarter last year, the firm posted $3.50 earnings per share. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. Analysts expect that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Insider Activity

In other news, Director Claire Fraser sold 917 shares of the business's stock in a transaction on Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total transaction of $171,937.50. Following the completion of the sale, the director owned 22,226 shares in the company, valued at $4,167,375. The trade was a 3.96% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Michael David Garrison sold 1,185 shares of the firm's stock in a transaction on Friday, July 18th. The stock was sold at an average price of $180.29, for a total value of $213,643.65. Following the completion of the transaction, the executive vice president owned 4,887 shares in the company, valued at $881,077.23. This represents a 19.52% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 3,023 shares of company stock worth $562,036. 0.36% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Northcape Wealth Management LLC boosted its holdings in shares of Becton, Dickinson and Company by 0.5% during the 1st quarter. Northcape Wealth Management LLC now owns 9,814 shares of the medical instruments supplier's stock worth $2,248,000 after buying an additional 51 shares during the period. Alpha Omega Wealth Management LLC raised its stake in Becton, Dickinson and Company by 5.7% in the 1st quarter. Alpha Omega Wealth Management LLC now owns 984 shares of the medical instruments supplier's stock worth $225,000 after purchasing an additional 53 shares in the last quarter. Brady Family Wealth LLC raised its stake in Becton, Dickinson and Company by 1.2% in the 1st quarter. Brady Family Wealth LLC now owns 4,317 shares of the medical instruments supplier's stock worth $989,000 after purchasing an additional 53 shares in the last quarter. Diversified Trust Co increased its holdings in shares of Becton, Dickinson and Company by 4.7% during the first quarter. Diversified Trust Co now owns 1,188 shares of the medical instruments supplier's stock worth $272,000 after purchasing an additional 53 shares during the period. Finally, Bill Few Associates Inc. grew its position in Becton, Dickinson and Company by 0.7% during the second quarter. Bill Few Associates Inc. now owns 7,906 shares of the medical instruments supplier's stock worth $1,362,000 after buying an additional 55 shares in the last quarter. 86.97% of the stock is currently owned by institutional investors.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.